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Abstract
Background: Control of latent tuberculosis infection (LTBI) is an important step towards tuberculosis elimination.
Preventive treatment will prevent the development of disease in most cases diagnosed with LTBI. However, low
initiation and completion rates affect the effectiveness of preventive treatment. The objective was to systematically
review data on initiation rates and completion rates for LTBI treatment regimens in the general population and
specific populations with LTBI.
Methods: A systematic review of the literature (PubMed, Embase) published up to February 2014 was performed.
Results: Forty-five studies on initiation rates and 83 studies on completion rates of LTBI treatment were found.
These studies provided initiation rates (IR) and completion rates (CR) in people with LTBI among the general population
(IR 26–99 %, CR 39–96 %), case contacts (IR 40–95 %, CR 48–82 %), healthcare workers (IR 47–98 %, CR 17–79 %),
the homeless (IR 34–90 %, CR 23–71 %), people who inject drugs (IR 52–91 %, CR 38–89 %), HIV-infected individuals
(IR 67–92 %, CR 55–95 %), inmates (IR 7–90 %, CR 4–100 %), immigrants (IR 23–97 %, CR 7–86 %), and patients with
comorbidities (IR 82–93 %, CR 75–92 %). Generally, completion rates were higher for short than for long LTBI
treatment regimens.
Conclusion: Initiation and completion rates for LTBI treatment regimens were frequently suboptimal and varied
greatly within and across different populations.
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Background
In the European Union and European Economic Area
(EU/EEA) 65 thousand cases of tuberculosis (TB) were
reported in 2013, of which 77 % had pulmonary TB [1].
Cases with pulmonary TB produce microscopic droplets
when coughing, sneezing, or spitting which can infect
other individuals [2]. Exposure to Mycobacterium tuber-
culosis may result in latent TB infection (LTBI), a state
in which the host immune system controls the replica-
tion of the bacillus to the extent that the progression to
TB disease is prevented [3, 4]. In a later phase, LTBI
may progress to TB disease, especially if the immune
system is compromised [3, 5]. Given that one-third of
the world population is estimated to be latently infected
with TB, there is a huge reservoir for the development of
future TB disease [6].
As long as a M. tuberculosis reservoir exists in individuals
with LTBI, elimination of TB will not be feasible. Thus, the
control of LTBI is an important step towards TB elimin-
ation. In addition to TB case detection and treatment, TB is
controlled by identifying individuals who are latently in-
fected with M. tuberculosis and offering them treatment
that will prevent the development of TB disease, especially
in high-income countries [7–9].
Several LTBI treatment regimens have shown effective-
nesss [10]. However, adherence to these treatment regi-
mens was sometimes low and differed between treatment
regimens and populations [8, 11–18]. Numerous reasons
for low adherence have been reported, such as (fear of)
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side effects of the treatment, lack of symptomatic disease
and thus lack of motivation for taking preventive treat-
ment, or low risk perception of progression to active TB
[11, 17, 19].
Incorporating programmatic LTBI control into the na-
tional and EU/EEA strategies to fight TB is likely to be
of value for all EU/EEA Member States. Therefore, the
European Centre for Disease Prevention and Control
(ECDC) aims to provide EU/EEA Member States and
candidate countries with scientific advice and guidance
on programmatic LTBI control. In order to collect the evi-
dence base for developing the ECDC guidance a series of
systematic reviews have been performed. This was done in
collaboration with World Health Organization (WHO)
who used the same evidence base for the development of
the WHO guidelines on LTBI control [20] launched in
early 2015. One important aspect for LTBI control is to
ensure adherence to and completeness of the preventive
treatment. Therefore, a systematic literature review was
performed to assess initiation and completion rates of
LTBI treatment and to identify determinants and inter-
ventions for adherence and completion, in the general and
in specific populations with LTBI. In this article we
present the results of the initiation and completion rates
for recommended preventive treatments.
Methods
A systematic literature review was performed according
to a review protocol and following the Cochrane guide-
lines. The aim of the systematic review was to provide
answers to the following research questions: 1) What is
the LTBI treatment initiation rate and the completion
rate for each recommended LTBI treatment regimen; 2)
What are determinants of LTBI treatment initiation, ad-
herence, and completion; 3) What are the interventions
with demonstrated efficacy or effectiveness to improve
LTBI treatment initiation, adherence and completion in
individuals who are eligible for LTBI treatment. Due to
the extensive results, the results for review question 1
are presented in this article and the results for review
questions 2 and 3 will be presented separately.
Eligibility criteria
PICO (Population-Intervention-Comparator-Outcome)
questions were formulated based on the review questions
(see Additional file 1: PICO questions). Only primary
articles describing randomised controlled trials (RCTs),
non-randomised prospective comparative studies of inter-
ventions, prospective longitudinal observational studies,
and retrospective studies were included in this review.
Systematic reviews were not included; however the refer-
ence lists of relevant systematic reviews were screened to
find primary articles that were not found via our literature
search. Studies in individuals eligible for LTBI treatment
were considered relevant. Eligibility for LTBI treatment
was defined as “being diagnosed with LTBI”. There was no
required minimum study duration or number of subjects,
except for studies in the general population diagnosed
with LTBI that also presented data stratified for specific
populations (e.g. case contacts, immigrants etc.). Since
these studies were primarily aimed at the total population,
and sampling strategies were applied accordingly, data for
the specific populations were only extracted when such a
population consisted of at least 30 subjects. Studies were
considered to be conducted in the general population
when they did not specifically focus on certain risk groups.
For an article to be included in the review, baseline data
(e.g. population characteristics) must be presented, LTBI
had to be defined in the study (e.g. as “positive tuberculin
skin tests (greater of equal 10 mm) and negative chest ra-
diographs”) and the LTBI treatment regimen had to be
specified, and for studies presenting completion rates, a
definition for “completion” had to be provided. Studies
did not have to apply a specific definition for LTBI or
completion to be included. Adherence rates that met the
definition of “completion” (e.g. “full adherence” or “ad-
herence for nine months”) were interpreted as comple-
tion rates. If individuals whose completion status was
pending by the end of a study were included in the
completion rate, the rate was recalculated to exclude
these individuals. Studies that included only case con-
tacts who received chemoprophylaxis irrespective of
whether or not LTBI was diagnosed were excluded
from this review.
Information sources and search strategy
We searched the databases PubMed and Embase. Search
strings were composed for 1) LTBI, 2) LTBI treatment,
and 3) initiation, adherence, completion and implemen-
tation. A fourth search string was composed to exclude
animal studies (see Additional file 2: Search strings). No
geographical, time, or language limits were applied, how-
ever only full-text articles in English, French, Spanish,
German, and Dutch were reviewed. The search was car-
ried out on February 3rd, 2014 for all literature published
up to that date. Output from the searched databases was
exported to Endnote version X4.0.2.
Study selection
Articles were selected by a three-step selection procedure
based on 1) screening of title and abstract, 2) screening of
full-text article, and 3) final screening during the data-
extraction phase. One-hundred percent of the title and ab-
stract selection and critical appraisal of the full-text articles
was done in duplicate by two independent researchers; the
results were compared and discussed and any doubts were
resolved by a third researcher.
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Risk of bias assessment
The risk of bias of each included full-text article was
assessed with standardised, study-design specific, quality
appraisal forms following the risk of bias assessment
proposed by the Cochrane Collaboration [21]. A few
additional aspects, not mentioned in the Cochrane Col-
laboration, were considered when evaluating the quality
of the articles, i.e. the adequacy of recall assessment and
reporting, whether confidence intervals were provided,
and for retrospective studies, the adequacy of the
method of retrospective selection of the population.
Each aspect was evaluated as high risk of bias, moderate
or unclear risk of bias, or low risk of bias. Because of
the descriptive nature of the review question, risk of bias
was only assessed for aspects of the individual studies,
without providing an overall level of quality for each in-
dividual study. As review question 1 does not deal with
the effects of health interventions and treatment and
populations vary widely between studies, risk of bias was
also not assessed across the evidence base per outcome.
Data extraction
Evidence tables were compiled by two researchers and
reviewed by a third researcher. The data extraction was
done in duplicate for 15 % of the included articles, no
major differences were found. Evidence tables were cre-
ated for different populations with LTBI: 1) general
population (primarily unselected individuals with LTBI
at clinics), 2) case contacts, 3) healthcare workers, 4) the
homeless, 5) people who inject drugs (PWID), 6) human
immunodeficiency virus (HIV)-infected individuals, 7)
inmates, 8) immigrants, and 9) patients with comorbidi-
ties, e.g. patients with rheumatoid arthritis or patients
with hematologic malignancies. The definitions of com-
pletion were those used in the individual studies; there
were differences in definitions between studies. Study re-
sults were sorted by study design and split by duration
of the LTBI treatment regimen, i.e. short (≤four months),
long (>four months), or short and long combined when
no data were presented for short and long LTBI treat-
ment separately.
Synthesis of results
Meta-analysis is performed in accordance with GRADE
methodology and results are reported in accordance with
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement. For data visualisa-
tion, forest plots of initiation and completion rates were
created for the identified populations in Excel 2010 [22].
The MetaXL 2.1 add-in in Excel was used to calculate
95 % confidence intervals around initiation and comple-
tion rates. We planned to calculate pooled rates, however
this was not done for the first review question, because of
the large heterogeneity of the included articles.
Results
Results of the review process
The search resulted in 2536 unique hits; 115 relevant ar-
ticles were included for all review questions (see Fig. 1).
For review question 1, a total of 95 unique articles were
found, including 43 prospective studies and 52 retrospect-
ive studies. Of these articles, 45 provided information on
initiation rates of LTBI treatment regimens and 83 on
completion rates. An overview of the study characteristics,
initiation and/or completion rates, and the quality aspects
of the risk of bias assessment of the included studies are
presented in Additional file 3: Study characteristics, out-
comes, and quality aspects.
Initiation and completion rates
Most study populations in the included articles consisted
of individuals from the general population diagnosed with
LTBI, case contacts or immigrants with LTBI (Table 1;
Additional file 3: Study characteristics, outcomes, and
quality aspects). In prospective studies, initiation and
completion rates were most often presented for long treat-
ment regimens and in retrospective studies rates were
most frequently reported for either long treatment regi-
mens or for short and long treatment regimens combined.
Initiation rates
Overall, twenty prospective studies [18, 19, 23–40] that
reported initiation rates were found (Table 1; Additional
file 3: Study characteristics, outcomes, and quality as-
pects). Initiation rates varied considerably among popula-
tions with LTBI, ranging from 26 to 99 % in the general
population (four studies [18, 23–25]) (Fig. 2), from 40 to
85 % in case contacts (four studies [25–28]), from 34 to
90 % in the homeless (three studies [25, 29, 30]), from 52
to 91 % in PWID (three studies [31–33]), from 90 to 92 %
in HIV-infected individuals (three studies [34–36]), and
from 23 to 97 % in immigrants (four studies [25, 38–40])
(Additional file 3: Study characteristics, outcomes, and
quality aspects). Only one prospective study each reported
an initiation rate in healthcare workers or inmates, the ini-
tiation rates for these groups were 98 % [19] and 65 %
[37], respectively. No prospective studies that reported ini-
tiation rates were found for patients with comorbidities.
Twenty-five retrospective studies that reported initi-
ation rates, mostly based on medical records, were found
(Table 1; Additional file 3: Study characteristics, outcomes,
and quality aspects). There was considerable overlap in the
ranges of initiation rates reported in prospective studies
and retrospective studies.
Completion rates
In total, 39 prospective studies reporting completion
rates were identified [12, 18, 23–27, 30–32, 34–62].
Completion rates ranged from 46 to 95 % in the general
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population (thirteen studies [12, 18, 23–25, 41, 42,
46, 47, 49, 50, 57, 60]), from 53 to 82 % in case con-
tacts (six studies [12, 25–27, 51, 52]), from 25 to
71 % in the homeless (four studies [18, 25, 30, 60]),
from 38 to 89 % in PWID (four studies [31, 32, 56, 58]),
from 55 to 95 % in HIV-infected individuals (eight studies
[18, 34–36, 44, 48, 54, 55]), from 4 to 48 % in inmates
(three studies [37, 53, 63]), and from 7 to 83 % in immi-
grants (nine studies [12, 25, 38–40, 43, 45, 57, 59]). Only
one study reported a completion rate in healthcare
workers and patients with comorbidities, the completion
rates for these groups were 44 % [18] and 87 % [61], re-
spectively. In addition, 44 retrospective studies reporting
completion rates were found (Table 1; Additional file 3:
Study characteristics, outcomes, and quality aspects).
Within-study comparisons show that the homeless had
lower completion rates than other populations [18, 25, 64].
As for initiation rates, considerable overlap in the ranges of
completion rates reported in prospective studies and retro-
spective studies appears to exist.
Short versus long treatment regimens
In most of the 27 studies that presented separate com-
pletion rates for patients that received short treatment
regimens and for patients that received long treatment
regimens, completion rates appear to be higher for the
short treatment group (Fig. 3; Additional file 4: Forest
plots). However, an exception to this observation was
Clerk et al., who showed higher completion rates for
long treatment regimens than shorter regimens (67 %
vs 79 %) [65], and a small number of other studies that
showed very similar completion rates between the two
treatment groups [48, 52, 66, 67] in various populations
with LTBI. Due to large heterogeneity across studies
Fig. 1 Flow chart of selection process. RQ: review question. LTBI: latent tuberculosis infection; TB: tuberculosis. Review question 1a: What is the
initiation rate for each recommended LTBI treatment regimen?; Review question 1b: What is the completion rate for each recommended LTBI
treatment regimen?; Review question 2a: What are the determinants of LTBI treatment initiation?; Review question 2b: What are the determinants
of LTBI treatment adherence?; Review question 2c: What are the determinants of LTBI treatment completion?; Review question 3: In individuals
who are eligible for LTBI treatment, what are the interventions with demonstrated efficacy or effectiveness to improve LTBI treatment initiation,
adherence and completion?
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Table 1 Number of included studies and ranges of initiation and completion rates per study population
Study population Short treatment regimens Long treatment regimens Short/long treatment regimens
combined
n Range rates (%) n Range rates (%) n Range rates (%) N
Initiation rates
Prospective studies (n = 20 unique articles; some present data for more than one population and more than one treatment regimen)
General 1 [23] 86 2 [18, 24] 44–99 1 [25] 26 4
Case contacts 0 – 3 [26–28] 40–85 1 [25] 53 4
Healthcare workers 1 [19] 98 0 – 0 – 1
Homeless 0 – 2 [29, 30] 76–90 1 [25] 34 3
PWID 0 – 3 [31–33] 52–91 0 – 3
HIV infected 0 – 2 [34, 35] 90–92 1 [36] 91 3
Inmates 0 – 1 [37] 65 0 – 1
Immigrants 0 – 3 [38–40] 77–97 1 [25] 23 4
Patients with
comorbidities
0 – 0 – 0 – 0
Retrospective studies (n = 25 unique articles; some present data for more than one population and more than one treatment regimen)
General 0 – 4 [89–92] 82–98 5 [16, 78, 93–95] 53–83 9
Case contacts 0 – 1 [96] 81 5 [13, 78, 97–99] 74–95 6
Healthcare workers 0 – 1 [100] 92 4
[78, 94, 101, 102]
47–89 5
Homeless 0 – 0 – 0 – 0
PWID 0 – 1 [103] 56 0 – 1
HIV infected 0 – 1 [104] 67 0 – 1
Inmates 0 – 0 – 2 [80, 105] 7–90 2
Immigrants 0 – 2 [106, 107] 78–84 3 [16, 93, 94] 57–82 5
Patients with
comorbidities
1 [108] 93 1 [109] 82 0 – 2
Completion rates
Prospective studies (n = 39 unique articles; some present data for more than one population and more than one treatment regimen)
General 10 [12, 23, 25, 41, 42,
46, 47, 49, 50, 60]
61–95 10 [12, 18, 24, 25, 41,
42, 46, 47, 50, 57]
46–76 0 – 13
Case contacts 2 [51, 52] 71–82 4 [26, 27, 51, 52] 53–73 2 [12, 25] 60–64 6
Healthcare workers 0 – 1 [18] 44 0 – 1
Homeless 1 [60] 71 2 [18, 30] 25–33 1 [25] 44 4
PWID 0 – 4 [31, 32, 56, 58] 38–89 0 – 4
HIV infected 6 [36, 44, 48] 62–95 8 [18, 34–36, 44, 48, 54,
55]
55–89 0 – 8
Inmates 1 [53] 48 3 [37, 53, 62] 4–38 0 – 3
Immigrants 2 [43, 59] 72–80 8 [38–40, 43, 45, 57] 7–83 2 [12, 25] 61–79 9
Patients with
comorbidities
1 [61] 87 0 – 0 – 1
Retrospective studies (n = 44 unique articles; some present data for more than one population and more than one treatment regimen)
General 14 [14–17, 65–67, 78,
79, 81–83, 110, 111]
56–93 23 [14–16, 64–67, 78,
79, 81–83, 89–92, 112–118]
39–96 1 [93] 54 27
Case contacts 3 [13, 14, 17] 63–69 4 [13, 14, 113, 116] 56–78 5 [78, 82, 97,
98, 119]
48–81 10
Healthcare workers 0 – 2 [100, 113] 17–75 3 [15, 78, 101] 40–79 5
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and the fact that most studies were not designed to
specifically assess the effect of treatment duration on
completion, no pooled analysis was performed to deter-
mine if there was a statistically significant association
between treatment duration and completion rates.
Discussion
This is, to our knowledge, the first systematic review to
comprehensively explore both initiation and completion
rates of LTBI treatment worldwide. In total, evidence from
95 studies has been reviewed. Forty-five studies reported
on initiation rates and 83 on completion rates, covering
nine different population types with LTBI. There was wide
variation in initiation and completion rates; the initiation
rates ranged from 7 to 99 % and the completion rates
ranged from 4 to 100 % across the different population
groups. These rates should be interpreted taking into ac-
count the variety of treatment options (i.e. choice of regi-
men, duration, self-administered or observed).
Risk groups
The population for which most studies were identified was
the general population diagnosed with LTBI. Though this
population consisted primarily of unselected individuals
with LTBI at clinics, it was very diverse, mainly due to the
varying proportion of specific populations, such as immi-
grants, across clinics. Generally, two types of risk groups
could be distinguished: groups with higher risk of TB
infection, but without an increased risk of progression
to TB (e.g. health care workers, inmates, and the home-
less) [68–70] and groups with LTBI who are at higher
risk of progression to active TB (e.g. HIV-infected indi-
viduals, patients with comorbidities) [71–74]. Case con-
tacts appear to have both a higher risk of TB infection
and a higher risk of progression to active TB due to re-
cent infection [68, 75]. The initiation rates and comple-
tion rates of LTBI treatment appeared slightly higher in
the groups with higher risk of progression of LTBI to
active TB than in the groups with higher risk of TB
Table 1 Number of included studies and ranges of initiation and completion rates per study population (Continued)
Homeless 1 [120] 44 1 [64] 23 0 – 2
PWID 0 – 1 [103] 55 0 – 1
HIV infected 0 – 2 [14, 104] 55–66 0 – 2
Inmates 4 [80, 120] 48–100 2 [80, 121] 23–68 0 – 3
Immigrants 4 [14, 16, 17, 122] 60–85 11 [14, 16, 64, 89, 91, 92,
106, 113, 116, 123, 124]





1 [108] 92 1 [125] 75 0 – 2





Initiation rates – General population with LTBI 
% (95%CI) 
Prospective  
Goswami et al., 2012 Combined 26 (22-30) 
Lee et al., 2011 Short 86 (79-92) 
Morano et al., 2013 Long 44 (38-50) 
Pettit et al., 2013 Long 99 (98-99) 
Retro-
spective  
Goswami et al., 2012 Combined 53 (52-54) 
Cruz et al., 2012 Long 98 (95-99) 
Gershon et al., 2004 Combined 58 (53-64) 
Gilroy et al., 2000 Long 98 (97-99) 
Horsburgh et al., 2010 Combined 83 (80-86) 
Kwara et al., 2008 Long 82 (79-84) 
Nuzzo et al., 2013 Combined 78 (75-80) 
Parsyan et al., 2007 Long 91 (90-93) 
Shah et al., 2012 Combined 77 (74-80) 
0 10 20 30 40 50 60 70 80 90 100
Fig. 2 Forest plots with ranges of initiation rates in the general population diagnosed with LTBI. LTBI: latent tuberculosis infection; Circle: combined,
square: long, triangle: short
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infection. Care has to be taken when comparing find-
ings between studies, due to differences within popula-
tions, in setting and in methodology.
Hirsch-Moverman et al. [11] reviewed studies in the
United States and Canada published between 1997 and
2007 and presented completion rates of LTBI treatment
that are in line with the results found in our review.
Overall, 20 of the 60 studies that were included in their
review were also included in ours; differences are due to
the fact that we did not include studies that did not pro-
vide a definition for completion, did not specify the type
of treatment or did not define LTBI.
Al-Darraji et al. [76] reviewed completion rates of
treatment with isoniazid in inmates with LTBI, from
studies published between 1966 and January 2011. Four
of the sixteen studies they included were also included
in our review. Both the presented completion rate of iso-
niazid treatment during incarceration and after release
from jail appeared slightly higher than the completion
rates of long LTBI treatment regimens in inmates found
in our review.
Short and long treatment regimens
Short LTBI treatment most frequently consisted of four
months of rifampicin or two months of rifampicin and
pyrazinamide, though other combinations of rifampicin,
isoniazid, rifabutin and pyrazinamide were also adminis-
tered for two to four months. Currently, the combin-
ation of rifampicin with pyrazinamide is not generally
offered to persons with LTBI as it has been associated
Design Study Duration regimen
Completion rates – General population with LTBI 
% (95%CI) 
RCT
Bastos et al., 2013 Short 82 (73-90) 
Bastos et al., 2013  Long 62 (51-72) 
Jasmer et al., 2002  Short 61 (55-66) 
Jasmer et al., 2002  Long 57 (51-62) 
Menzies et al., 2008  Short 78 (74-82) 
Menzies et al., 2008  Long 60 (55-64) 
Menzies et al., 2004  Short 91 (83-97) 
Menzies et al., 2004  Long 76 (64-86) 
Schechter et al., 2006 (1)  Short 93 (89-96) 
Schechter et al., 2006 (2)  Short 94 (90-97) 
Spyridis et al., 2007  (1) Short 95 (92-98) 
Spyridis et al., 2007 (2)  Short 93 (91-95) 
Spyridis et al., 2007  Long 86 (81-90) 
Trajman et al., 2010  Short 81 (77-85) 
Trajman et al., 2010  Long 64 (59-69) 
Prospective 
Goswami et al., 2012  Short 68 (50-83) 
Goswami et al., 2012  Long 52 (42-61) 
Lee et al., 2011  Short 93 (87-98) 
Morano et al., 2013  Long 60 (49-69) 
Morisky et al., 2003  Long 69 (65-73) 
Pettit et al., 2013  Long 47 (45-50) 
Stout et al., 2003  Short 68 (59-76) 
Retro-
spective 
Cain et al., 2012  Combined 54 (53-56) 
Chang SH et al., 2013  Long 78 (76-80) 
Clerk et al., 2011  Short 67 (53-81) 
Clerk et al., 2011  Long 79 (53-97) 
Codecasa et al., 2013 Long 74 (73-75) 
Cruz et al., 2012  Long 75 (69-80) 
Cruz et al., 2013  Long 96 (94-97) 
Duarte et al., 2012  Short 93 (90-95) 
Duarte et al., 2012  Long 90 (85-94) 
Fresard et al., 2011  Short 83 (77-88) 
Fresard et al., 2011  Long    74 (70-78) 
Gilroy et al., 2000  Long 51 (46-55) 
Haley et al., 2008  Short 76 (73-79) 
Hirsch-Moverman et al., 2010  Long 45 (39-50) 
Horsburgh et al., 2010  Short 64 (55-73) 
Horsburgh et al., 2010  Long 46 (44-48) 
Kan et al., 2013  Long 76 (71-80) 
Kwara et al., 2008  Long 62 (58-65) 
Lardizabal et al., 2006  Short 80 (75-85) 
Lardizabal et al., 2006  Long 53 (46-60) 
Li et al., 2010  Short 60 (57-63) 
Li et al., 2010  Long 44 (43-45) 
LoBue et al., 2003  Long 64 (62-65) 
Nuzzo et al., 2013  Short 80 (75-84) 
Nuzzo et al., 2013  Long 72 (67-78) 
Page et al., 2006  Long 53 (49-56) 
Parsyan et al., 2007  Long 39 (36-41) 
Rennie et al., 2007  Short 60 (55-66) 
Rennie et al., 2007  Long 46 (40-52) 
Smith et al., 2011  Short 56 (52-61) 
Smith et al., 2011  Long 54 (53-55) 
Vinnard et al., 2013  Long 46 (39-52) 
Young et al., 2009  Short 91 (85-95) 
Young et al., 2009  Long 65 (61-69) 
0 10 20 30 40 50 60 70 80 90 100
Fig. 3 Forest plot with completion rates in the general population diagnosed with LTBI. LTBI: latent tuberculosis infection; Circle: combined,
square: long, triangle: short
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with hepatotoxicity [77]. Long LTBI treatment consisted
of isoniazid regimens, usually for six or nine months and
often for twelve months in the case of concurrent HIV-
infection. Only three studies presented initiation rates
for short treatment regimens, therefore initiation rates
between short and long treatment regimens could not
be compared.
A considerable number of prospective articles pre-
sented completion rates for both short and long treat-
ment regimens, especially in the general population
diagnosed with LTBI and in HIV-infected individuals
with LTBI. Most results of within-study comparisons of
short and long treatments [13–16, 78–83] indicated
higher completion rates for shorter regimens, although
in two studies rates were comparable for short and long
treatment regimens [66, 67]. In one study lower comple-
tion rates were reported for short treatment than for
longer treatments [65] due to adverse effects. It should
be kept in mind that the type of drugs used in short and
long LTBI treatment regimens varied considerably between
studies and within populations.
Hirsch-Moverman et al. [11] also reviewed data on
completion rates of short (rifampicin or rifampicin in
combination with pyrazinamide) and long (isoniazid)
treatment regimens within studies and found a higher per-
centage of completion among short treatments in all in-
cluded studies, although the difference was not always
significant. Ziakas et al. [84] systematically reviewed the
literature for studies that compared four months of rifam-
picin with nine months of isoniazid, published up to July
2009, and included four studies in a meta-analysis. These
four studies were also included in this review. They con-
cluded that four months of rifampicin was associated with
a significant reduction in the risk of non-completion [84].
Sharma et al. [85] conducted a systematic review on RCTs
worldwide among HIV-negative people at risk of active
TB that compared rifampicin monotherapy or rifamycin-
combination therapy with isoniazid monotherapy. Their
meta-analysis of five trials, of which two were included in
our review, compared rifampicin (three or four months)
with isoniazid (six months) and showed that significantly
more people completed the shorter course. Two more of
their meta-analyses compared isoniazid in combination
with rifampicin (three months; two trials) or rifampicin in
combination with pyrazinamide (two months; three trials,
one of which was included in our review) with isoniazid
(six months) and found that there was no difference in
completion rates [85].
By comparing completion rates between short and long
LTBI treatment we do not take into account any effect of
the treatment regimen on completion rate, e.g. due to dif-
ferent side effect patterns. The effect of different treatment
regimens for preventing active TB, and thus indirectly
taking into account completion, has been compared by
Stagg et al. [10] and was part of the same evidence base
collection as our systematic review.
Limitations
Studies without a definition for “completion” were ex-
cluded from this review. Still, the definition of completion
varied considerably between studies, and this hetero-
geneity complicated comparison of completion rates
between studies. Definitions used varied from “com-
pleted four months of rifampicin” [81] to “picked up
nine months of isoniazid within twelve months” [25]
and “took at least 80 % of the prescribed medication
within twenty weeks” [15]. Also, the quality of the defi-
nitions of “completion” varied throughout the included
studies and the distinction between definitions for adher-
ence and completion was not always obvious. Besides, the
quality of the definition of “completion” is closely linked
to the way treatment adherence is assessed, which varied
from self-reported adherence (least reliable) [35], dispense
of medication [58], pill counts [52], urine tests [43], to
Directly Observed Treatment (DOT; most reliable) [62].
Furthermore, it was not always clear whether and to what
extent the classification of a patient as having completed
treatment was influenced by the time that a patient
needed to take all the doses. Finally, some patients may
have discontinued treatment due to toxicity. In our ana-
lysis, this is included in non completion. Discontinuation
because of side effects will influence the effectiveness of
latent TB infection treatment but it will need other efforts
than voluntary discontinuation of treatment.
In addition, rate calculations varied across included
studies; different rules were applied for in- and exclusion
into the denominator to calculate the initiation and/or
completion rates. All these differences between studies
and unclarities hampered the analysis.
Within our review, no distinction was made between
studies that looked at a priori defined risk groups versus
studies that identified risk factors in a non-selected group
of individuals with LTBI. Also, population characteristic
or settings of risk groups may vary between studies, for
example immigrants in the United States might differ
from immigrants in Europe with respect to their origin
[86, 87]. In addition, it should be noted that individuals
with LTBI might belong to multiple risk groups, as overlap
between the groups exists; however, most studies did not
specify if there was any overlap between risk groups.
Conclusions
The goal of LTBI treatment is to eradicate M. tuberculosis
from the body and to reduce the risk of progression to ac-
tive TB disease [88]. Only treatment can clear the bacteria
from the body, and therefore individuals with LTBI who
do not initiate treatment contribute to the persistence of
the TB reservoir. Clinical benefit to the individual with
Sandgren et al. BMC Infectious Diseases  (2016) 16:204 Page 8 of 12
LTBI and the success of control programs is subject to
completion of LTBI treatment.
This systematic review found that initiation and com-
pletion rates for LTBI treatment regimens were fre-
quently suboptimal and varied greatly within and across
different populations. Population groups with a higher risk
of TB infection, but without an increased risk of progres-
sion to TB (e.g. health care workers, inmates, and the
homeless) seemed at slightly higher risk of low initiation
and completion rates. However, the limited number of
studies found for certain LTBI treatment regimens and
study populations, and the variation in types of risk popu-
lations, settings, treatment regimens and study methodolo-
gies in the included studies make it difficult to draw firm
conclusions.
Considering the sub-optimal rates of completion, imple-
menting interventions to improve the adherence and com-
pletion rates in groups most at risk of developing active TB
seems relevant to make LTBI treatment more effective and
decrease the spread of TB.
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